|
Characteristics
|
Total (n = 106)
|
TPX2
|
P value
|
|---|
|
Negative (n = 35)
|
Positive (n = 71)
|
|---|
|
Gender
|
|
Male
|
67 (63.2 %)
|
22 (32.8 %)
|
45 (67.2 %)
|
0.958
|
|
Female
|
39 (36.8 %)
|
13 (33.3 %)
|
26 (66.7 %)
|
|
Age (years)
|
|
≥60
|
46 (43.4 %)
|
7 (15.2 %)
|
39 (84.8 %)
|
0.001
|
|
<60
|
60 (56.6 %)
|
28 (46.7 %)
|
32 (53.3 %)
|
|
T stage
|
|
1
|
10 (9.4 %)
|
8 (80 %)
|
2 (20 %)
|
0.003
|
|
2
|
10 (9.4 %)
|
4 (40 %)
|
6 (60 %)
|
|
3
|
84 (79.2 %)
|
22 (26.2 %)
|
62 (73.8 %)
|
|
4a
|
2 (1.9 %)
|
1 (50 %)
|
1 (50 %)
|
|
N stage
|
|
0
|
21 (19.8 %)
|
10 (47.6 %)
|
11 (35.2 %)
|
0.120
|
|
1
|
38 (35.8 %)
|
14 (36.8 %)
|
24 (63.2 %)
|
|
3
|
47 (44.3 %)
|
11 (6.3 %)
|
36 (3.6 %)
|
|
M stage
|
|
0
|
99 (93.4 %)
|
34 (34.3 %)
|
65 (65.7 %)
|
0.421
|
|
1
|
7 (6.6 %)
|
1 (14.3 %)
|
6 (85.7 %)
|
|
TNM stage
|
|
I
|
13 (12.3 %)
|
5 (38.5 %)
|
8 (61.5 %)
|
0.144
|
|
II
|
17 (16.0 %)
|
8 (47.1 %)
|
9 (52.9 %)
|
|
III
|
69 (65.1 %)
|
22 (31.9 %)
|
47 (68.1 %)
|
|
IV
|
7 (6.3 %)
|
0 (0 %)
|
7 (100 %)
|
|
Tumor size (cm)
|
|
≥5
|
74 (69.8 %)
|
24 (32.4 %)
|
50 (67.6 %)
|
1.000
|
|
<5
|
32 (30.2 %)
|
11 (34.4 %)
|
21 (65.6 %)
|
- The results of immune-histochemical score were determined by the average score that given by two pathologists, immune-reactivities were scored by the intensity of staining (0, no staining; 1 weak = light yellow; 2 moderate = yellow brown; 3 strong = brown) and the percentage of stained cells (0 no staining; 1, 0–10 %; 2, 11–30 %; 3, 31–70 %; 4, >71 %). By multiplication of both values, a final score ranging between 0 and 12 was obtained. TPX2 over-expression was defined as final score more than zero
